Background: Dermatomyositis (DM)/ polymyoitis (PM) are systemic diseases characterized by muscle inflammation, which shows varieties of clinical symptoms and signs. We have experienced cases of DM/PM with generalized edema as reported previously by others (1). Moreover, we found that there were many myositis patients who lost their body weight (BW) after starting of high dose glucocorticoid (GC) therapy. Thus, we hypothesized that hidden generalized edema is a characteristic clinical feature of myositis. Objectives: To determine whether generalized edema is a hidden clinical feature of myositis. If so, what myositis patients have the feature. Methods: The study was a retrospective observation study. The subjects were consecutive 67 of DM/PM and 53 of SLE patients who diseases for the first time, admitted our department from April 2007 to September 2016 and received immunosuppressive therapy including over 30mg/day GC. The patients were excluded who had cardiogenic or nephrogenic edema or whose BW data was not available. To detect hidden generalized edema caused by inflammation, we examined the change in BW within 2 weeks after starting immunosuppressive therapy. The clinical features of DM/PM patients with/without BW change were examined through reviewing medical record. Results: The included subjects were DM/PM 66 patients (M/F; 18/48 with a mean age of 59.4 y.) and SLE 40 patients (M/F;14/26 with a mean age of 49.8 y.). The body weight of DM/PM and SLE were 56.4±14.0 and 54.7±10.9 kg, respectively. Decrease in BW within 2weeks after starting the therapy were 3.02±2.99kg of DM/PM and 0.85±2.87 kg of SLE, which was larger in DM/PM compared to SLE (Fig A) . The numbers of patients who lost BW more than 2kg within the 2 weeks were 42 in DM/PM (64%) and 14 in SLE (35%). Serum albumin levels were slightly decreased by 0.18 g/ dl (0.06 to 0.30; 95% CI) in DM/PM, while no significant change was detected in SLE. In myositis, change in BW was similar among DM, amyopathic DM (ADM) and PM (Fig.B) . Moreover, no differences were found in the change of BW between patients with and without male sex, malignancy, interstitial pneumonia, anti-ARS Ab and anti-MDA5Ab. Additionally, between patients with and without BW loss more than 2kg, no differences were found in age, serum TP, Alb and CRP levels before and after treatment and prognosis. Background: Annual incidence rates of inflammatory myopathies (IM) vary widely from 1.16-19.0 per 10 6 of adults.1 Our aim was to, for the first time, determine the incidence rate of IM in our population. Objectives: To determine the incidence rate of IM in our population. Methods: We retrospectively collected incident cases of IM from 1 January 2005 to 31 December 2016 at our department of rheumatology which is a part of an integrated secondary/tertiary university teaching hospital that is the only referral center for two well defined regions representing roughly a third of the national adult population. Tertiary cases are referred to our department from the entire country. We identified the cases by searching the electronic patient records (PRs) for ICD-10 codes M05, M33-35, M60, G73.7, G72.4. The paper and electronic PRs were scrutinized to assess clinical, laboratory and histopathological data. Descriptive statistics was used to describe our group of patients. The adult population size of the two regions served by our department was obtained from the national statistics institute database. The annual incidence rate for IM was then calculated. Results: During the 12-year observation period we identified 117 new cases of IM from a well-defined adult white Caucasian population aged 18 or above. 38 cases were excluded from analyses since they were referred to our department from outside the two regions we serve on the secondary and tertiary level. Thus, we analyzed 79 cases of IM (63% female; median (IQR) age 67 (55-75) years; 44% ever smokers). The median time to diagnosis was 5 (IQR 3-12) months. We diagnosed 29% patients with dermatomyositis, 25% with anti-synthetase syndrome, 18% with polymyositis, 9% with statin induced necrotizing autoimmune myopathy, 9% with concomitant myositis as a part of connective tissue disease, 6% with paraneoplastic myositis, and 4% with undifferentiated myositis. The IM cases were most often diagnosed in the summer months (32.9%), followed by spring (24.1%), fall (22.8%), and winter (20.3%). The clinical and laboratory characteristics at presentation are shown in Table 1 . Muscle biopsy was performed in 93% of patients. Notably, patients with swallowing difficulties had more commonly had Raynaud phenomenon (RR 3.7 (95% CI 1.4-9.4), p=0.008).
Conclusions

Conclusions:
The averaged 12-year annual incidence of IM in the population under study was 9.4 (95% CI 7.5-11.8) per 10 6 adults. utility of the measurement of serum trough IFX and antibodies to IFX (ATI). In India, many centres including ours use IFX at lower doses of 3-5 mg/kg and on demand IFX treatment without the use of the loading dose IFX in SpA patients 3 . Data on the utility of measuring trough IFX and ATI levels and their correlation with disease activity in such group of patients is lacking. Objectives: To evaluate the co-relation between trough Infliximab levels and disease activity measures, viz ASDAS ESR and ASDAS CRP in SpA patients on low dose IFX therapy To compare the mean ASDAS-ESR/CRP scores between ATI positive and ATI negative patients Methods: Thirty-nine adult spondyloarthrtitis patients in the age group of 18-70 years, meeting the ASAAS classification criteria for peripheral and/or axial spondyloarthritis were recruited into the study. The inclusion criteria required the patients to have had received three or more infusions of IFX at 3-5 mg/kg/dose over the past 6 to 9 months. Blood samples were collected between two to three months after the previous IFX infusion for the measurement of the ATI and the trough IFX levels using the Matriks Biotek Shikari Q-ATI ELISA and Q-IFLIXI ELISA kits respectively. At the same time, disease activity of the patients was quantitated using ASDAS ESR and ASDAS CRP scores.
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Correlation between the ASDAS scores and the trough IFX levels was analysed by Pearson's product moment correlation assay. The difference in mean trough IFX and ASDAS scores between the ATI positive and ATI negative patients were assessed using Welch two sample t-test. Results: There was a moderately significant negative correlation between the trough IFX levels and the ASDAS-ESR (r = -0.69, p<0.001), ASDAS-CRP scores (r = -0.67, p<0.001) (Fig 1) . ATI positive patients in comparison to ATI negative, had significantly higher ASDAS ESR and ASDAS CRP scores (Table 1) . 
